A Phase 1/2 interventional study of Lenvatinib and Everolimus in Recurrent and Refractory Solid Tumors, sponsored by Eisai Inc.. Completed at 50 sites in 2 countries. Open to participants aged 2 Years to 21 Years. Per ClinicalTrials.gov, last updated 2023-08-30.
Sponsored by Eisai Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Central Nervous System Neoplasms with a site in United States — 46 open to participants now, 74 under way, 3 of them phase 3. Central Nervous System Neoplasms · United States.
Among the 547 studies in Central Nervous System Neoplasms with a site in United States, this one is the 106th largest by enrollment of the 399 interventional ones that give a count, is one of 22 that started in 2017, is one of 70 in phase 1/2, and was the 448th registered.
699 studies on the registry are indexed under Central Nervous System Neoplasms; 66 are open to participants now.
Browse Central Nervous System Neoplasms studies →46 of the 547 studies in Central Nervous System Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Neonc Technologies, Inc. · Sites in United States
Ages 5–18
BrainChild Bio, Inc · Sites in United States
Ages 1–26
Robbie Majzner · Sites in United States
Ages 2–21
University of California, Irvine · Sites in United States
Ages 18+
National Institute of Neurological Disorders and Stroke (NINDS) · Sites in United States
Ages 18–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 57 Central Nervous System Neoplasms studies recruiting now, 35 (61%) set no upper age limit and 19 (33%) stop at 75 or younger; 35 take children under 18; 6 take healthy volunteers.
This study: 2 Years to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 256 · Phase 2 241 · Phase 3 22 · Phase 4 1
First in 1989; this study’s year is marked. 22 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is above the median of 35 across 487 interventional studies indexed under Central Nervous System Neoplasms.
Median enrollment 31 across the 399 interventional studies, 109 across the 68 observational. Of the 436 that completed or were terminated, 109 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 547 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Eisai Co., Ltd. has 1 study filed under Central Nervous System Neoplasms — fewer than ten, so there is no comparison to draw.
23 of the studies in Central Nervous System Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT05664243In8bio Inc.A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma | 2026-12 |
| NCT05386108Stemline Therapeutics, Inc.Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | 2026-12 |
| NCT05425004Baptist Health South FloridaCabozantinib for Patients With Recurrent or Progressive Meningioma | 2026-12 |
| NCT05762419Columbia UniversityFUS Etoposide for DMG | 2026-12 |
Add all 23 to your calendar (.ics) → With an account.
Among the 547 studies in Central Nervous System Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 1 of this study, utilizing a rolling 6 design, will be conducted to determine a maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), and to describe the toxicities of lenvatinib administered in combination with everolimus once daily to pediatric participants with recurrent/refractory solid tumors. Phase 2, utilizing Simon's optimal 2-stage design, will be conducted to estimate the antitumor activity of lenvatinib in combination with everolimus in pediatric participants with selected recurrent/refractory solid tumors including Ewing sarcoma, rhabdomyosarcoma, and high grade glioma (HGG) using objective response rate (ORR) at Week 16 as the outcome measure.
699 studies on the registry are indexed under Central Nervous System Neoplasms; 66 are open to participants now.
This study's enrollment of 64 is above the median of 35 across 487 interventional studies indexed under Central Nervous System Neoplasms.
Browse Central Nervous System Neoplasms studies →Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Compared within Central Nervous System Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Recurrent or solid tumors
Measurable disease that meets the following criteria (Phase 2):
Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF) ablation must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion
Prior Therapy
Exclusion Criteria
Participants who have had or are planning to have the following invasive procedures
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During Phase 1 (Treatment Phase: 1 cycle; 28 days of treatment), utilizing a rolling 6 design, participants with recurrent or refractory solid tumors will receive escalating doses of lenvatinib in combination with everolimus for determination of the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). Participants who complete 1 cycle of treatment will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
Drug: Lenvatinib · Drug: Everolimus
During Phase 2 (four 28-day cycles \[up to 16 weeks of treatment\]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory Ewing sarcoma (Cohort 1) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1. Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
Drug: Lenvatinib · Drug: Everolimus
During Phase 2 (four 28-day cycles \[up to 16 weeks of treatment\]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory rhabdomyosarcoma (Cohort 2) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1 (1 cycle; 4 weeks of treatment). Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
Drug: Lenvatinib · Drug: Everolimus
During Phase 2 (four 28-day cycles \[up to 16 weeks of treatment\]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory HGG (Cohort 3) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1 (1 cycle; 4 weeks). Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
Drug: Lenvatinib · Drug: Everolimus
oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension
2 mg, 3 mg, or 5 mg tablets for oral suspension
Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib in Combination With Everolimus
MTD was defined as the highest dose level at which no more than 1/6 participants experienced a dose limiting toxicity (DLTs), with the next higher dose having at least 0 of 3 or 1 of 6 participants experiencing DLTs. DLT was graded according to common terminology criteria for adverse events (CTCAE) version 4.03.
Time frame: Cycle 1 (Each cycle was of 28 days)
Phase 1: Recommended Phase 2 Dose (RP2D) of Lenvatinib in Combination With Everolimus
The RP2D of lenvatinib in combination with everolimus was determined by Dose Escalation Committee (DEC) based on safety (including DLTs), pharmacokinetic and clinical data. DLT was graded according to CTCAE v4.03.
Time frame: Cycle 1 (Each cycle was of 28 days)
Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
A TEAE was defined as an adverse event that emerged during treatment, having been absent at pretreatment or reemerged during treatment, having been present at pretreatment but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the adverse event is continuous. An adverse event was defined as any untoward medical occurrence in a participant administered an investigational product.
Time frame: From date of first dose up to 28 days after the last dose of study treatment (Up to 17.5 months)
Phase 1: Number of Participants With Any Treatment-emergent Serious Adverse Event (TESAE)
A TESAE was any untoward medical occurrence that at any dose: resulted in death; life threatening condition; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or was medically important due to other reasons than the above mentioned criteria. An adverse event was defined as any untoward medical occurrence in a participant administered an investigational product.
Time frame: From date of first dose up to 28 days after the last dose of study treatment (Up to 17.5 months)
Phase 2: Objective Response Rate (ORR) at Week 16
ORR at Week 16 was defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) at Week 16 based on investigator assessment according to response evaluation criteria in solid tumors (RECIST) version 1.1 for non-HGG cohorts and response assessment in neuro-oncology (RANO) for HGG cohort. CR was defined as disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis less than (\<) 10 millimeter (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameter (SOD) of target lesions, taking as reference the baseline sum diameters.
Time frame: Week 16
Phase 1: Objective Response Rate (ORR)
ORR was defined as the percentage of participants with BOR of CR or PR based on investigator assessment according to RECIST version 1.1 for non-HGG cohorts and RANO for HGG cohort. CR was defined as disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters.
Time frame: From the date of the first dose of study drug to the date of first documentation of disease progression or death, whichever occurred first (up to 16.5 months)
Phase 2: Objective Response Rate (ORR)
ORR was defined as the percentage of participants with BOR of CR or PR based on investigator assessment according to RECIST version 1.1 for non-HGG cohorts and RANO for HGG cohort. CR was defined as disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters.
Time frame: From the date of the first dose of study drug to the date of first documentation of disease progression or death, which ever occurred first (up to 6.5 months)
Phase 1: Disease Control Rate (DCR)
DCR was defined as percentage of participants with a confirmed CR, PR, or stable disease (SD) (SD duration \>=7 weeks since the first dose of study treatment) divided by number of participants in analysis set. DCR was assessed by an investigator based on RECIST v1.1 for non-HGG participants or RANO for HGG participants. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
Time frame: From first dose of study drug until PD or death, whichever occurred first (up to 16.5 months)
Phase 2: Disease Control Rate (DCR)
DCR was defined as percentage of participants with confirmed CR, PR, or SD (SD duration greater than or equal to \[\>=\] 7 weeks since first dose of study treatment) divided by number of participants in analysis set. DCR was assessed by investigator based on RECIST v1.1 for non-HGG cohorts or RANO for HGG cohort. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
Time frame: From first dose of study drug until PD or death, whichever occurred first (up to 6.5 months)
Phase 1: Clinical Benefit Rate (CBR)
CBR was defined as percentage of participants who had BOR of CR, PR, or durable SD (SD duration \>=23 weeks since the first dose of study treatment) divided by number of participants in analysis set. CBR was assessed by an investigator based on RECIST v1.1 for non-HGG participants or RANO for HGG participants. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
Time frame: From first dose of study drug until PD or death, whichever occurred first (up to 16.5 months)
Phase 2: Clinical Benefit Rate (CBR)
CBR was defined as percentage of participants who had BOR of CR, PR, or durable SD (SD duration \>=23 weeks since the first dose of study treatment) divided by number of participants in analysis set. CBR was assessed by an investigator based on RECIST v1.1 for non-HGG cohorts or RANO for HGG cohort. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
Time frame: From first dose of study drug until PD or death, whichever occurred first (up to 6.5 months)
Phase 1: Duration of Response (DOR)
DOR was defined as the time (in months) from the date of first observation of confirmed response (PR or CR) to the date of the first observation of progression based on the investigator's assessment utilizing RECIST 1.1 for non-HGG cohorts and RANO for HGG cohorts, or date of death, whatever the cause. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
Time frame: From date of the first observation of CR or PR until the date of first observation of progression or date of death (up to 16.5 months)
Phase 2: Duration of Response (DOR)
DOR was defined as the time (in months) from the date of first observation of confirmed response (PR or CR) to the date of the first observation of progression based on the investigator's assessment utilizing RECIST 1.1 for non-HGG cohorts and RANO for HGG cohort, or date of death, whatever the cause. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
Time frame: From date of the first observation of CR or PR until the date of first observation of progression or date of death (up to 6.5 months)
Phase 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration of Lenvatinib (AUC[0-t Hours])
AUC0-t of lenvatinib was quantified using validated liquid chromatography tandem mass spectrometry (LC-MS/MS) methods.
Time frame: Cycle 1 Days 1 and 15: 0-8 hours post-dose (Cycle length=28 days)
Phase 1: Maximum Plasma Concentration of Lenvatinib (Cmax)
Cmax of lenvatinib was quantified using validated liquid LC-MS/MS methods.
Time frame: Cycle 1 Days 1 and 15: 0-8 hours post-dose (Cycle length=28 days)
Phase 1: Time to Reach Maximum Plasma Concentration (Cmax) of Lenvatinib (Tmax)
Tmax of lenvatinib was quantified using validated liquid LC-MS/MS methods.
Time frame: Cycle 1 Days 1 and 15: 0-8 hours post-dose (Cycle length=28 days)
Phase 1: Trough Concentrations (Ctrough) of Everolimus When Administered in Combination With Lenvatinib
Trough concentrations of everolimus was quantified using validated liquid LC-MS/MS methods.
Time frame: Cycle 1 Days 1, 2, 15 and 22: Pre-dose (Cycle length=28 days)
Phase 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
A TEAE was defined as an adverse event that emerged during treatment, having been absent at pretreatment or reemerged during treatment, having been present at pretreatment but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the adverse event is continuous. An adverse event was defined as any untoward medical occurrence in a participant administered an investigational product.
Time frame: From date of first dose up to 28 days after the last dose of study treatment (up to 7.5 months)
Phase 2: Number of Participants With Any Treatment-emergent Serious Adverse Event (TESAE)
A TESAE was any untoward medical occurrence that at any dose: resulted in death; life threatening condition; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or was medically important due to other reasons than the above mentioned criteria. An adverse event was defined as any untoward medical occurrence in a participant administered an investigational product.
Time frame: From date of first dose up to 28 days after the last dose of study treatment (up to 7.5 months)
Participants took part in the study at 24 investigative sites in the United States and Canada from 16 November 2017 to 30 September 2022.
| Milestone | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 | Phase 2: Cohort 1, Ewing Sarcoma | Phase 2: Cohort 2, Rhabdomyosarcoma | Phase 2: Cohort 3, HGG |
|---|---|---|---|---|---|
| Started | 5 | 18 | 10 | 20 | 11 |
| Completed | 0 | 3 | 1 | 2 | 3 |
| Not completed | 5 | 15 | 9 | 18 | 8 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 2 | 1 |
| Withdrew: Death | 3 | 14 | 9 | 16 | 7 |
| Withdrew: Sponsor's decision | 0 | 1 | 0 | 0 | 0 |
MTD was defined as the highest dose level at which no more than 1/6 participants experienced a dose limiting toxicity (DLTs), with the next higher dose having at least 0 of 3 or 1 of 6 participants experiencing DLTs. DLT was graded according to common terminology criteria for adverse events (CTCAE) version 4.03.
| milligram per square meter (mg/m^2) | Phase 1: Lenvatinib + Everolimus (All Participants) |
|---|---|
| Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib in Combination With Everolimus | 11 |
The RP2D of lenvatinib in combination with everolimus was determined by Dose Escalation Committee (DEC) based on safety (including DLTs), pharmacokinetic and clinical data. DLT was graded according to CTCAE v4.03.
| mg/m^2 | Phase 1: Lenvatinib + Everolimus (All Participants) |
|---|---|
| Phase 1: Recommended Phase 2 Dose (RP2D) of Lenvatinib in Combination With Everolimus | 11 |
A TEAE was defined as an adverse event that emerged during treatment, having been absent at pretreatment or reemerged during treatment, having been present at pretreatment but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the adverse event is continuous. An adverse event was defined as any untoward medical occurrence in a participant administered an investigational product.
| Participants | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 |
|---|---|---|
| Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 5 | 18 |
A TESAE was any untoward medical occurrence that at any dose: resulted in death; life threatening condition; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or was medically important due to other reasons than the above mentioned criteria. An adverse event was defined as any untoward medical occurrence in a participant administered an investigational product.
| Participants | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 |
|---|---|---|
| Phase 1: Number of Participants With Any Treatment-emergent Serious Adverse Event (TESAE) | 2 | 12 |
ORR at Week 16 was defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) at Week 16 based on investigator assessment according to response evaluation criteria in solid tumors (RECIST) version 1.1 for non-HGG cohorts and response assessment in neuro-oncology (RANO) for HGG cohort. CR was defined as disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis less than (\<) 10 millimeter (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameter (SOD) of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Phase 2: Cohort 1, Ewing Sarcoma | Phase 2: Cohort 2, Rhabdomyosarcoma | Phase 2: Cohort 3, HGG |
|---|---|---|---|
| Phase 2: Objective Response Rate (ORR) at Week 16 | 0.0 ± 0.0 | 10.0 ± 1.2 | 0 ± 0.0 |
ORR was defined as the percentage of participants with BOR of CR or PR based on investigator assessment according to RECIST version 1.1 for non-HGG cohorts and RANO for HGG cohort. CR was defined as disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 |
|---|---|---|
| Phase 1: Objective Response Rate (ORR) | 0.0 ± 0.0 | 0.0 ± 0.0 |
ORR was defined as the percentage of participants with BOR of CR or PR based on investigator assessment according to RECIST version 1.1 for non-HGG cohorts and RANO for HGG cohort. CR was defined as disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Phase 2: Cohort 1, Ewing Sarcoma | Phase 2: Cohort 2, Rhabdomyosarcoma | Phase 2: Cohort 3, HGG |
|---|---|---|---|
| Phase 2: Objective Response Rate (ORR) | 0.0 ± 0.0 | 10.0 ± 1.2 | 0.0 ± 0.0 |
DCR was defined as percentage of participants with a confirmed CR, PR, or stable disease (SD) (SD duration \>=7 weeks since the first dose of study treatment) divided by number of participants in analysis set. DCR was assessed by an investigator based on RECIST v1.1 for non-HGG participants or RANO for HGG participants. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
| percentage of participants | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 |
|---|---|---|
| Phase 1: Disease Control Rate (DCR) | 20.0 ± 0.5 | 50.0 ± 26.0 |
DCR was defined as percentage of participants with confirmed CR, PR, or SD (SD duration greater than or equal to \[\>=\] 7 weeks since first dose of study treatment) divided by number of participants in analysis set. DCR was assessed by investigator based on RECIST v1.1 for non-HGG cohorts or RANO for HGG cohort. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
| percentage of participants | Phase 2: Cohort 1, Ewing Sarcoma | Phase 2: Cohort 2, Rhabdomyosarcoma | Phase 2: Cohort 3, HGG |
|---|---|---|---|
| Phase 2: Disease Control Rate (DCR) | 40.0 ± 12.2 | 40.0 ± 19.1 | 30.0 ± 6.7 |
CBR was defined as percentage of participants who had BOR of CR, PR, or durable SD (SD duration \>=23 weeks since the first dose of study treatment) divided by number of participants in analysis set. CBR was assessed by an investigator based on RECIST v1.1 for non-HGG participants or RANO for HGG participants. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
| percentage of participants | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 |
|---|---|---|
| Phase 1: Clinical Benefit Rate (CBR) | 20.0 ± 0.5 | 22.2 ± 6.4 |
CBR was defined as percentage of participants who had BOR of CR, PR, or durable SD (SD duration \>=23 weeks since the first dose of study treatment) divided by number of participants in analysis set. CBR was assessed by an investigator based on RECIST v1.1 for non-HGG cohorts or RANO for HGG cohort. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
| percentage of participants | Phase 2: Cohort 1, Ewing Sarcoma | Phase 2: Cohort 2, Rhabdomyosarcoma | Phase 2: Cohort 3, HGG |
|---|---|---|---|
| Phase 2: Clinical Benefit Rate (CBR) | 20.0 ± 2.5 | 10.0 ± 1.2 | 0.0 ± 0.0 |
DOR was defined as the time (in months) from the date of first observation of confirmed response (PR or CR) to the date of the first observation of progression based on the investigator's assessment utilizing RECIST 1.1 for non-HGG cohorts and RANO for HGG cohorts, or date of death, whatever the cause. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
No measurements were reported for this outcome.
DOR was defined as the time (in months) from the date of first observation of confirmed response (PR or CR) to the date of the first observation of progression based on the investigator's assessment utilizing RECIST 1.1 for non-HGG cohorts and RANO for HGG cohort, or date of death, whatever the cause. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
| months | Phase 2: Cohort 1, Ewing Sarcoma | Phase 2: Cohort 2, Rhabdomyosarcoma | Phase 2: Cohort 3, HGG |
|---|---|---|---|
| Phase 2: Duration of Response (DOR) | — | 2.4 (2.1 to NA) | — |
AUC0-t of lenvatinib was quantified using validated liquid chromatography tandem mass spectrometry (LC-MS/MS) methods.
| nanogram*hour per milliliter (ng*hr/mL) | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 |
|---|---|---|
| Cycle 1 Day 1 | 2338.0 ± 1633.41 | 3281.1 ± 1064.72 |
| Cycle 1 Day 15 | 1328.0 ± 520.69 | 2139.8 ± 1156.48 |
Cmax of lenvatinib was quantified using validated liquid LC-MS/MS methods.
| nanogram per milliliter (ng/mL) | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 |
|---|---|---|
| Cycle 1 Day 1 | 240.20 ± 130.892 | 404.13 ± 121.473 |
| Cycle 1 Day 15 | 314.20 ± 149.527 | 447.62 ± 272.790 |
Tmax of lenvatinib was quantified using validated liquid LC-MS/MS methods.
| hours | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 |
|---|---|---|
| Cycle 1 Day 1 | 3.000 (2.000 to 4.000) | 2.890 (1.000 to 7.78) |
| Cycle 1 Day 15 | 3.950 (2.000 to 8.05) | 2.950 (0 to 8.02) |
Trough concentrations of everolimus was quantified using validated liquid LC-MS/MS methods.
| ng/mL | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 |
|---|---|---|
| Cycle 1 Day 1: Pre-dose | 0.0 ± 0.0 | 0.0 ± 0.00 |
| Cycle 1 Day 2: Pre-dose | 2.1 ± 1.34 | 2.2 ± 1.13 |
| Cycle 1 Day 15: Pre-dose | 3.2 ± 2.42 | 5.1 ± 2.98 |
| Cycle 1 Day 22: Pre-dose | 2.8 ± 1.96 | 4.2 ± 2.73 |
A TEAE was defined as an adverse event that emerged during treatment, having been absent at pretreatment or reemerged during treatment, having been present at pretreatment but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the adverse event is continuous. An adverse event was defined as any untoward medical occurrence in a participant administered an investigational product.
| Participants | Phase 2: Cohort 1, Ewing Sarcoma | Phase 2: Cohort 2, Rhabdomyosarcoma | Phase 2: Cohort 3, HGG |
|---|---|---|---|
| Phase 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 10 | 19 | 11 |
A TESAE was any untoward medical occurrence that at any dose: resulted in death; life threatening condition; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or was medically important due to other reasons than the above mentioned criteria. An adverse event was defined as any untoward medical occurrence in a participant administered an investigational product.
| Participants | Phase 2: Cohort 1, Ewing Sarcoma | Phase 2: Cohort 2, Rhabdomyosarcoma | Phase 2: Cohort 3, HGG |
|---|---|---|---|
| Phase 2: Number of Participants With Any Treatment-emergent Serious Adverse Event (TESAE) | 6 | 8 | 8 |
Collected over From date of first dose up to 28 days after the last dose of study treatment (Phase 1: Up to 17.5 months; Phase 2: Up to 7.5 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | 4/5 (80%) | 2/5 (40%) | 5/5 (100%) |
| Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 | 14/18 (77.8%) | 12/18 (66.7%) | 18/18 (100%) |
| Phase 2: Cohort 1, Ewing Sarcoma | 9/10 (90%) | 6/10 (60%) | 10/10 (100%) |
| Phase 2: Cohort 2, Rhabdomyosarcoma | 17/20 (85%) | 8/20 (40%) | 19/20 (95%) |
| Phase 2: Cohort 3, HGG | 8/11 (72.7%) | 8/11 (72.7%) | 11/11 (100%) |
| Event | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 | Phase 2: Cohort 1, Ewing Sarcoma | Phase 2: Cohort 2, Rhabdomyosarcoma | Phase 2: Cohort 3, HGG |
|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 0/5 | 0/18 | 3/10 | 1/20 | 0/11 |
| PainGeneral disorders | 1/5 | 2/18 | 0/10 | 1/20 | 0/11 |
| HeadacheNervous system disorders | 1/5 | 1/18 | 0/10 | 0/20 | 1/11 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/5 | 0/18 | 2/10 | 1/20 | 0/11 |
| SeizureNervous system disorders | 0/5 | 3/18 | 0/10 | 0/20 | 2/11 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/5 | 3/18 | 1/10 | 1/20 | 0/11 |
| Back painMusculoskeletal and connective tissue disorders | 0/5 | 2/18 | 0/10 | 0/20 | 0/11 |
| SepsisInfections and infestations | 0/5 | 0/18 | 1/10 | 0/20 | 0/11 |
| Upper respiratory tract infectionsInfections and infestations | 0/5 | 0/18 | 0/10 | 2/20 | 0/11 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/5 | 0/18 | 1/10 | 0/20 | 0/11 |
| Event | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 | Phase 2: Cohort 1, Ewing Sarcoma | Phase 2: Cohort 2, Rhabdomyosarcoma | Phase 2: Cohort 3, HGG |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 4/5 | 5/18 | 3/10 | 9/20 | 4/11 |
| StomatitisGastrointestinal disorders | 4/5 | 5/18 | 2/10 | 9/20 | 2/11 |
| Lymphocyte count decreasedInvestigations | 3/5 | 6/18 | 8/10 | 11/20 | 2/11 |
| Decreased appetiteMetabolism and nutrition disorders | 4/5 | 4/18 | 2/10 | 6/20 | 2/11 |
| HypophosphataemiaMetabolism and nutrition disorders | 1/5 | 3/18 | 8/10 | 6/20 | 1/11 |
| Back painMusculoskeletal and connective tissue disorders | 4/5 | 1/18 | 1/10 | 4/20 | 2/11 |
| ProteinuriaRenal and urinary disorders | 1/5 | 8/18 | 8/10 | 10/20 | 4/11 |
| HypertensionVascular disorders | 4/5 | 13/18 | 3/10 | 10/20 | 4/11 |
| HyponatraemiaMetabolism and nutrition disorders | 1/5 | 6/18 | 7/10 | 2/20 | 1/11 |
| DiarrhoeaGastrointestinal disorders | 3/5 | 10/18 | 5/10 | 8/20 | 7/11 |
Safety Analysis Set (SAS) included all participants who received at least 1 dose of study drug (lenvatinib or everolimus).
| Age, Customized(Participants) | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 | Phase 2: Cohort 1, Ewing Sarcoma | Phase 2: Cohort 2, Rhabdomyosarcoma | Phase 2: Cohort 3, HGG | Total |
|---|---|---|---|---|---|---|
| 2-11 years | 0 | 16 | 3 | 9 | 3 | 31 |
| 12-17 years | 4 | 1 | 3 | 6 | 7 | 21 |
| 18-64 years | 1 | 1 | 4 | 5 | 1 | 12 |
| Sex: Female, Male(Participants) | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 | Phase 2: Cohort 1, Ewing Sarcoma | Phase 2: Cohort 2, Rhabdomyosarcoma | Phase 2: Cohort 3, HGG | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 10 | 3 | 8 | 8 | 31 |
| Male | 3 | 8 | 7 | 12 | 3 | 33 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 | Phase 2: Cohort 1, Ewing Sarcoma | Phase 2: Cohort 2, Rhabdomyosarcoma | Phase 2: Cohort 3, HGG | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 7 | 2 | 2 | 0 | 12 |
| Not Hispanic or Latino | 4 | 11 | 8 | 18 | 11 | 52 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 | Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2 | Phase 2: Cohort 1, Ewing Sarcoma | Phase 2: Cohort 2, Rhabdomyosarcoma | Phase 2: Cohort 3, HGG | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 1 |
| Asian | 0 | 1 | 1 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 0 | 1 | 3 | 6 |
| White | 3 | 11 | 9 | 16 | 6 | 45 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 4 | 0 | 3 | 2 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in Sep 2022, 58 months.
Results were first posted in Aug 2023, 11 months after primary completion.
Of 35 phase 1/2 interventional studies under Central Nervous System Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 85. This study's 58 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenvatinib
Central Nervous System Neoplasms →